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OBJECTIVES We sought to investigate the impact of six months of cardiac resynchronization therapy
(CRT) on echocardiographic variables of left ventricular (LV) function.
BACKGROUND Cardiac resynchronization therapy has recently been introduced as a new therapeutic modality
in patients with advanced heart failure (HF) and conduction abnormalities. However, most
studies have only investigated the early hemodynamic effects of CRT.
METHODS Twenty-five patients (12 women and 13 men; 59.8 5.1 years old) with advanced HF caused
by ischemic (n  7) or idiopathic dilated cardiomyopathy (n  18) and a prolonged QRS
complex were analyzed. All patients underwent early hemodynamic testing with a randomized
testing protocol; echocardiographic measurements were compared before implantation and
after six months of CRT.
RESULTS Left ventricular end-diastolic and end-systolic diameters (LVEDD and LVESD, respec-
tively) were significantly reduced after six months (LVEDD from 71  10 to 68  11 mm,
p 0.027; LVESD from 63 11 to 58 11 mm, p 0.007), as were LV end-diastolic and
end-systolic volumes (LVEDV from 253  83 to 227  112 ml, p  0.017; LVESV from
202  79 to 174  101 ml, p  0.009). Ejection fraction was significantly increased (from
22  7% to 26  9%, p  0.03). “Nonresponders,” with regard to LV volume reduction, had
significantly higher baseline LVEDV, compared with “responders” (351  52 vs. 234 
74 ml, p  0.018). Overall, there was only mild mitral regurgitation at baseline, with a minor
reduction by semiquantitative analysis. The results of early hemodynamic testing did not
predict the volume response.
CONCLUSIONS Cardiac resynchronization therapy may lead to a reduction in LV volumes in patients with
advanced HF and conduction disturbances. Volume nonresponders have significantly higher
baseline LVEDV. (J Am Coll Cardiol 2001;38:1957–65) © 2001 by the American College
of Cardiology
Cardiac resynchronization therapy (CRT) acts by recoordi-
nating ventricular activation using atrial synchronous left or
biventricular (BV) pacing. Early hemodynamic improve-
ment using this approach has been demonstrated in patients
with systolic heart failure (HF) (1–3). However, not all
patients improve hemodynamically with pacing (2), and
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variables predictive of early hemodynamic and long-term
functional improvement with pacing have not been fully
elucidated. Moreover, there are only few reports on the
long-term response of patients treated with this new ap-
proach (4). It is not yet clear whether early changes observed
during invasive testing predict a favorable long-term out-
come. Left ventricular (LV) volumes and ejection fraction
(EF), as assessed by two-dimensional echocardiography,
have been shown to be of prognostic importance in patients
with LV dysfunction (5). Thus, the aim of the present study
was to investigate whether CRT leads to long-term im-
provement in LV diameters and function in patients with
HF and a wide QRS complex and whether baseline echo-
cardiographic variables are predictive of long-term improve-
ment.
METHODS
Patient group and study design. The PAcing THerapies
in Congestive Heart Failure (PATH-CHF) study included
42 patients. All patients gave written, informed consent to
take part in the study, which was performed in compliance
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with the Human Studies Committee of each institution.
The design and inclusion and exclusion criteria of the study
have been described previously (6). In brief, patients with
HF of both ischemic and nonischemic origin were included
if they were in New York Heart Association (NYHA)
functional class III or IV HF and had sinus rhythm, a PR
interval150 ms and a QRS width120 ms in at least two
surface electrocardiographic (ECG) leads. QRS durations
were automatically measured as the maximum of leads II,
V1 and V6 and validated manually by two independent
observers. All patients underwent implantation of two
separate DDD pacemakers—one connected to a right atrial
and right ventricular (RV) screw-in pacing lead (Sweet-Tip,
Guidant Corp.) and the other connected to another right
atrial and epicardial LV pacing lead (model 4316, Guidant
Corp., or model 4965, Medtronic)—by a limited thoracot-
omy. This configuration allowed for a change of the pacing
site from RV to LV and BV pacing both during implanta-
tion and at long-term follow-up. Biventricular pacing was
achieved by programming one device in the VDD mode and
the second device in the ventricular triggered mode (VVT).
Early hemodynamic testing. All patients underwent early
hemodynamic testing during pacemaker implantation, un-
der general anesthesia. Two 8F dual-transducer pressure
catheters (model SPC-780c, Millar Instruments) were
placed to measure the right atrial, RV, LV and aortic
pressures. Pressure catheters and pacing leads were con-
nected to a customized external pacing computer (FlexStim,
Guidant Corp.) to acquire hemodynamic signals and exe-
cute an early pacing protocol (FlexStim protocol) (6). The
FlexStim protocol is designed to measure the immediate
effects of pacing, account for local baseline shifts and allow
statistical comparison of multiple pacing combinations
within individuals. Briefly, the RV, LV or both ventricles
were stimulated in the VDD mode at one of five atrioven-
tricular delays preset to a percentage of the patient’s intrinsic
PR interval, as measured with the pacing leads. Each
combination of pacing chamber and atrioventricular delay
was randomly repeated five times by pacing for five beats
separated by 15 nonpaced beats. The hemodynamic vari-
ables used to determine the optimized pacing mode were
the changes in aortic pulse pressure and maximal upward
slope of the LV systolic pressure curve (dP/dt) (2).
Pacing protocol. For intra-individual comparisons of the
primary end point of the trial—improvement of functional
capacity (6)—patients were randomized to one month of
optimized univentricular or BV pacing followed by one
month of no pacing. During the third month, patients were
crossed over to the other pacing mode. After three months,
all patients were paced in the mode with the optimal early
response during intra-operative testing. The functional
status of the patient was assessed by a physician who had no
knowledge of the pacing mode before implantation and
after six months. Twenty-five patients (13 men and 12
women; 60  5 years old) were analyzed; 17 patients had to
be excluded for the following reasons: 4 patients died (1 due
to sudden cardiac death, 1 due to nonsudden cardiac death,
1 due to liver cancer, 1 postoperatively [this patient was later
classified as having an inclusion criteria violation, according
to the Data Safety Monitoring Committee, because of an
underestimated aortic stenosis]); 1 patient was in atrial
fibrillation at the six-month follow-up; 1 patient underwent
cardiac transplantation; 3 patients were not effectively paced
because of an increased LV pacing threshold; and 1 patient
withdrew consent. In the remaining seven patients, either
one of the echocardiograms was judged as insufficient for
reliable analysis by one or both independent observers.
Echocardiographic measurements. Transthoracic echo-
cardiography was performed shortly before pacemaker im-
plantation during intrinsic conduction and after six months
when patients were paced with the optimal mode and
settings. Left atrial and LV diameters were determined
using M-mode echocardiography under two-dimensional
guidance in the parasternal long-axis view, according to the
guidelines of the American Society of Echocardiography
(7). Left ventricular mass was calculated according to the
Penn convention (8). The end of diastole was defined by the
onset of the QRS complex in the simultaneously recorded
ECG; the end of systole was defined by the smallest cavity
area before mitral valve closure. For measurement of LV
end-systolic and end-diastolic dimensions (LVEDD and
LVESD, respectively), images were obtained in the apical
two- and four-chamber views. Percent fractional shortening
was calculated as: (LVEDDLVESD)/LVESD  100.
Longitudinal and transverse LV diameters were measured in
the apical four-chamber view at end diastole, and the
sphericity index was calculated as the LV transverse diam-
eter/longitudinal diameter ratio (9). Biplane LV end-
systolic and end-diastolic volumes (LVESV and LVEDV,
respectively) were calculated from the two-chamber and
four-chamber views, according to the modified Simpson’s
rule (10); measurements were averaged from three cardiac
cycles. Left ventricular EF was calculated as: LVEDV
 LVESV/LVEDV  100. Patients were classified
as volume “responders” if LVESV decreased by 15%, as
“stable” if LVESV changes were 15% and as “nonre-
sponders” if LVESV increased by 15%, based on data
Abbreviations and Acronyms
BV  biventricular
CRT  cardiac resynchronization therapy
HF  heart failure
LVEDD  left ventricular end-diastolic diameter
LVEDV  left ventricular end-diastolic volume
LVESD  left ventricular end-systolic diameter
LVESV  left ventricular end-systolic volume
EF  ejection fraction
LV  left ventricular
MR  mitral regurgitation
RV  right ventricular
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Table 1. Individual Patient Data (n  25)
Patient
No.
Age
(years) Gender Etiology
NYHA
Functional
Class
Interval
PR
(ms)
Duration
QRS
(ms)
BBB
Type
Early Response
Long-Term
Pacing Site
and AV
Delay (ms)
EDV (ml) ESV (ml) EF (%)Maximal
PP
Increase
(%)
dP/dt
Increase
(%) Baseline
6
Months Baseline
6
Months Baseline
6
Months
1 61 F Nonischemic 3 200 220 LBBB 13.8 16.1 LV:110 364 362 312 258 14 29
2 58 M Nonischemic 4 210 160 LBBB 19.8 45.0 BV:100 334 296 305 242 9 18
3 59 M Nonischemic 4 210 160 LBBB 13.0 24.0 LV:90 315 262 244 227 23 13
4 65 F Ischemic 3 180 140 LBBB 2.2 17.2 BV:140 93 94 70 55 25 42
5 60 F Nonischemic 3 165 140 LBBB 24.8 34.1 BV:100 167 90 123 73 27 19
6 63 M Nonischemic 3 220 200 LBBB 5.8 6.9 RV:110 205 172 147 134 28 22
7 66 M Ischemic 3 240 120 IVCD 0.8 0.6 RV:160 175 119 110 76 37 36
8 47 M Nonischemic 3 180 160 LBBB 16.6 45.3 BV:70 254 219 224 168 12 23
9 63 M Nonischemic 3 250 190 LBBB 25.4 31.9 BV:100 423 528 396 461 6 13
10 62 M Nonischemic 3 270 130 IVCD 0.9 1.6 BV:190 239 224 164 179 32 20
11 54 M Nonischemic 3 160 200 LBBB 31.9 54.9 BV:70 362 421 285 361 21 14
12 61 F Nonischemic 3 160 180 LBBB 15.7 20.6 LV:70 174 147 130 108 25 27
13 61 F Ischemic 3 200 120 IVCD 2.5 2.7 LV:140 168 128 139 96 18 25
14 59 M Ischemic 3 180 160 LBBB 2.0 13.1 BV:120 292 286 225 233 23 19
15 64 M Ischemic 3 220 180 LBBB 41.3 39.5 LV:70 279 320 198 236 29 26
16 62 F Nonischemic 3 220 160 LBBB 18.9 33.0 LV:120 179 122 146 78 18 36
17 64 F Nonischemic 3 220 200 LBBB 10.7 20.7 LV:100 318 218 265 149 17 32
18 59 F Ischemic 3 140 160 RBBB 0.3 5.0 BV:110 243 164 186 126 24 23
19 58 M Nonischemic 3 200 140 LBBB 4.4 1.8 RV:150 342 385 270 328 21 15
20 49 M Ischemic 3 220 150 LBBB 6.1 25.7 LV:80 156 155 131 101 16 35
21 59 F Nonischemic 3 220 170 LBBB 6.8 14.9 BV:90 241 121 179 89 26 27
22 65 F Nonischemic 3 250 150 LBBB 1.6 4.5 BV:150 291 238 221 151 24 37
23 67 F Nonischemic 3 160 175 LBBB 12.3 17.7 LV:100 332 277 285 206 14 26
24 50 F Nonischemic 3 205 130 LBBB 2.6 9.3 LV:130 163 166 121 105 26 37
25 59 M Nonischemic 3 230 180 LBBB 15.7 25.4 BV:100 220 160 168 101 24 37
Mean  SD 60  5 3.1  0.3 204  33 163  27 11.8  10.8 20.5  15.3 253  83 227  112 202  79 174  101 22  7 26  9
AV  atrioventricular; BBB  bundle branch block; BV  biventricular; dp/dt  maximal rise of left ventricular pressure; EDV and ESV  end-diastolic and end-systolic volume, respectively; EF  ejection fraction; IVCD 
intraventricular conduction disturbance; LBBB and RBBB  left and right bundle branch block, respectively; LV  left ventricle; NYHA  New York Heart Association; PP  pulse pressure; RV  right ventricle.
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showing a variability of 15% for repeated volume calcu-
lations derived from two-dimensional echocardiographic
measurements (11). For statistical analysis, responders and
stable patients were analyzed as one group, because both
reduced and stable volumes were regarded as a positive
clinical response to CRT. Mitral regurgitation (MR) was
semiquantitatively graded on a 4-point scale (grades 0 to 3)
using color-coded Doppler signals, as previously described
(12), and the maximal jet area was measured in the
parasternal and apical views (13). All examinations were
recorded, stored on videotape and analyzed at the respon-
sible core center (RWTH University of Technology,
Aachen, Germany). Final analysis was performed off-line
(from videotape) by two independent observers, after man-
ual recalibration on an Agilent Sonos 2500 ultrasound
scanner.
Concomitant drug treatment. Patients had to be in stable
NYHA functional class III HF without a change in medi-
cation or in class IV without the need for intravenous
inotropic drugs during the last month to be eligible for study
inclusion. Of the 25 patients, 24 (96%) were taking
angiotensin-converting enzyme inhibitors, 22 (88%) were
receiving digitalis, and 11 (44%) were receiving nitrates. Of
14 patients (56%) initially taking beta-blockers, the dosage
was constant in nine, reduced in two and increased in three
after six months. In only one patient was a beta-blocker
started during the study period. Of 24 patients (96%) taking
diuretics before implantation, the dosage was kept constant
in 12, reduced in 10 and increased in two. One patient
began to receive diuretics during the six-month period,
whereas diuretics were withdrawn in one patient.
Statistical analysis. The statistical methods used for anal-
ysis of the invasively measured hemodynamic variables have
been described elsewhere (2). In brief, relative changes of
dP/dt and pulse pressure (%) in the second to fifth paced
beats of each run of five paced beats were compared with the
average value during the immediately preceding six non-
paced beats. A paired t test was used to evaluate the effects
of pacing compared with no pacing. Cardiac dimensions
and volumes were compared intra-individually by using a
paired t test. Baseline volumes were compared with early
changes in dP/dt and pulse pressure by using linear regres-
sion analysis. All numeric data are expressed as the mean value
 SD. A p value 	0.05 was considered significant. Inter-
observer and intra-observer variabilities were defined as the
difference of measurements between two observers, expressed
as the percent difference ( SD) of the first observer.
RESULTS
Baseline evaluation. Table 1 shows the clinical data of the
25 analyzed patients. The ECG pattern of intraventricular
conduction delay was classified as left bundle branch block
(LBBB) type in 21 patients (84%), right bundle branch
block type in one patient (4%) and intraventricular conduc-
tion delay in three patients (12%), according to previously
published criteria (14). The optimal pacing site was BV in
12 (48%), LV in 10 (40%) and RV in 3 patients (12%). The
mean NYHA functional class improved from 3.0  0.1 at
baseline to 1.9  0.7 after six months of CRT, with no
difference between volume responders and stable patients
(n  21; from 3.0  0.2 to 1.9  0.7) and volume
nonresponders (n  4; from 3.0  0 to 2.1  0.9; p  NS).
Changes in LV dimensions, EF and mass. Table 2 shows
the M-mode echocardiographic variables. After six months
of therapy, LVESD and LVEDD were both reduced,
without a significant increase in fractional shortening. Left
atrial diameter and septal thickness remained unaffected.
Two-dimensional echocardiography revealed a significant
decrease of the transverse (6.8  1.1 vs. 6.2  1.4 cm, p 
0.02), but not the longitudinal (9.3  1.3 vs. 8.9  1.2 cm,
p  NS), LV diameter. Changes in the sphericity index
failed to reach the level of statistical significance (0.75 0.1
vs. 0.70  0.11, p  0.07). Figure 1 shows an example of
the volume changes observed; Figures 2 and 3 illustrate the
changes in LVEDV and LVESV, as well as LVEF. There
was a significant decrease in both LVEDV and LVESV
after six months of CRT, whereas EF showed a modest
increase. Intra-observer variability was 8.4  6.4% for
LVEDV and 9.4  7.1% for LVESV, compared with 33 
30% for EF. For inter-observer variability, the correspond-
ing values were 7.4  5.7%, 9.3  5.6% and 34.6  37.2%,
respectively. There was no change in LV mass (372  120
vs. 387  144 g, p  NS) or mean heart rate (78.5  17.2
vs. 74.4  20.2 beats/min, p  NS).
Comparison of responders and stable patients versus
nonresponders. Sixteen patients showed a reduction of
15% in LVESV; five were stable; and only four were
classified as nonresponders. These four patients had a
significantly higher mean baseline LVEDV value (Table 3).
The baseline volumes of responders (LVEDV: 232 
78 ml; LVESV: 187 74 ml) and stable patients (LVEDV:
243  62 ml; LVESV: 180  52 ml) did not differ
significantly. There were no significant differences in base-
line EF between the groups. After six months of CRT, EF
showed an increase only in volume responders (22  7% to
28  8%, p 	 0.001), whereas the nonresponders showed a
nonsignificant decrease in EF (20  10% to 17  6%, p 
NS). Eleven of 16 volume responders were receiving beta-
Table 2. M-Mode Echocardiographic Variables
Before
Implantation 6 Months
p
Value
LVEDD (mm) 71  10 (57–98) 68  11 (52–94) 0.027
LVESD (mm) 63  11 (44–87) 58  11 (45–83) 0.007
FS (%) 12  6 (4–24) 15  7 (4–33) NS
LAD (mm) 40  6 (33–52) 41  8 (31–67) NS
IVST (mm) 9  2 (5–14) 10  2 (7–13) NS
LV mass (g) 372  120 387  134 NS
Data are presented as the mean value  SD.
FS  fractional shortening; IVST  interventricular septal thickness; LAD  left
atrial diameter; LVEDD  left ventricular enddiastolic diameter; LVESD  left
ventricular endsystolic diameter.
1960 Stellbrink et al. JACC Vol. 38, No. 7, 2001
Cardiac Resynchronization Therapy and LV Remodeling December 2001:1957–65
blocker therapy, as were two of five stable patients and one
of four nonresponders.
Effect on MR. Most patients showed either no MR (grade
0, n  6) or only mild MR (grade 1, n  13) before
implantation. Five patients were classified as grade 2 and
one patient as grade 3. In the 19 patients who had at least
some degree of MR at baseline, there was improvement in
nine and increase in two. In the remaining eight patients,
the severity of MR was unaltered. No patient developed new
MR with pacing. The MR jet area was not significantly
altered (3.8  3.6 vs. 3.3  2.1 cm2, p  NS). There were
no differences in the degree of MR before implantation or
after six months of CRT between volume responders, stable
patients and nonresponders.
Figure 1. These end-diastolic echocardiographic images were obtained in the apical four-chamber view before device implantation (left) and after six
months of cardiac resynchronization therapy (right), where a volume reduction is demonstrated. The endocardial borders were manually delineated, and
the left ventricular (LV) cavity area surrounded by these borders was used for LV volume calculation, as explained in the text. Note the reduction in
end-diastolic volume and the reduced sphericity of the LV shape in the right image.
Figure 2. A comparison of left ventricular end-diastolic volume (LVEDV) (A) and left ventricular end-systolic volume (LVESV) (B) before pacemaker
implantation and after six months of hemodynamically optimized pacing. There was a significant decrease in both volumes after six months.
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Comparison of pre-implantation volumes, early hemo-
dynamic responses and long-term volume responses. No
correlation between baseline volumes and the early increase
in either aortic pulse pressure or dP/dt induced by CRT
was observed (Fig. 4A and 4B). Volume nonresponders
were found among those with very large and only minimal
early hemodynamic response.
DISCUSSION
Main findings. This study demonstrates that CRT
achieved by hemodynamically optimized pacing leads to a
long-term reduction in LV volumes in the majority of
patients with systolic HF and ventricular conduction dis-
turbances. Recent data in larger populations have indicated
reduced LVEDD after CRT (15). However, measurements
of LV volumes are more reliable in assessing LV remodeling
(16). The fact that the effect on LV diameters was more
pronounced for the transverse than for the longitudinal
diameter underscores a “reverse remodeling” effect caused by
CRT, although changes in the derived sphericity index
failed to reach statistical significance because of a minor,
nonsignificant decrease in the longitudinal LV diameter.
The spherical shape in dilated hearts is associated with
increased wall stress (17), and changes in LV sphericity have
been correlated to an increase in exercise capacity (18).
Effect on MR. Some investigators have speculated that
LV-based pacing leads to a reduction in MR (19), which
can be explained by 1) a reduction in presystolic MR by
optimizing atrioventricular delay and 2) a reduction in
systolic MR by improved coaptation of the valve leaflets,
which may be impaired by delayed contraction of the
anterolateral papillary muscle. The sphericity associated
with LV dilation leads to functional MR (20); thus, reversal
of this process may reduce MR. However, the degree of
baseline MR in our study was low; thus, despite the fact that
some reduction was noted, it seems unlikely that this was
the prevailing mechanism for LV volume reduction.
Prediction of volume response. Some patients did not
respond to CRT with a reduction in LV volumes, and the
extent of the early hemodynamic response was not a good
predictor of volume effects. In fact, three of four volume
nonresponders were among those with the largest early
hemodynamic improvement. Thus, other factors are in-
volved in the reverse remodeling response to CRT, such as
baseline geometry and LV size. The fact that volume
nonresponders had a higher mean LVEDV is in concor-
dance with data from drug trials indicating that nonre-
sponders to pharmacologic therapy had higher baseline
LVEDD values (21). However, our data do not yet allow for
the conclusion that CRT is not indicated in very dilated
hearts, because the positive early hemodynamic effects of
CRT can still lead to symptomatic improvement despite the
lack of volume reduction, as shown by a similar improve-
ment in NYHA functional class in volume nonresponders.
Moreover, we could not define a cut-off value above which
a reduction in LV volumes can no longer be expected.
Interaction with drug treatment. A dose-related “reverse
remodeling effect” in HF has been described for beta-
blocker treatment (22,23). An additive effect of beta-
blockers on volumes in our study cannot be completely ruled
out, because there were more volume responders than
nonresponders receiving beta-blocker therapy. However,
patients were receiving stable drug therapy before study
Figure 3. A comparison of echocardiographically determined ejection fraction (EF) before pacemaker implantation and after six months of hemodynam-
ically optimized pacing. There was a small but significant increase in EF after six months.
Table 3. Baseline Volumes of Chronic “Volume
Non-responders” Compared to Stable Patients and
“Volume Responders”
Volume
Non-Responders
(n  4)
Volume Responders
and Stable Patients
(n  21) p
Baseline EDV [ml] 351  60 234  74 0.018
EDV change [%] 17.1  4.7 18.6  15.1 	0.001
Baseline ESV [ml] 287  82 178  67 0.083
ESV change [%] 21.1  3.8 24.6  15.8 *
Baseline EF [%] 19.5  9.5 21.9  6.9 n.s.
EF change [%] 2.6  6.2 5.8  9.7 0.066
*Used as criterion to define responders and non-responders; for abbreviations see text.
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inclusion, and dose adjustments during the study were
minor, as indicated by the lack of a significant change in
heart rate. Moreover, recent data suggest that patients with
a QRS width 120 ms, as in our study, are less likely to
respond to beta-blocker therapy with an improvement in
EF, compared with patients with a narrow QRS width (24).
It is also noteworthy that 5 of 16 volume responders were
not taking beta-blockers. We believe that CRT is comple-
mentary to beta-blockers because: 1) it leads to an improve-
ment in exercise capacity (4), which has not been consis-
tently shown for beta-blockers; 2) it minimizes the risk of
bradyarrhythmias; and 3) it can be useful in the early
treatment phase to overcome the initial negative inotropy
and hypotension associated with beta-blockers. Cardiac
resynchronization therapy is an attractive alternative to
positive inotropic drug therapy for this purpose, because the
hemodynamic benefit achieved by CRT is associated with a
reduction in myocardial oxygen demand (25). The reason
Figure 4. Percent change in dP/dt (A) and pulse pressure (PP) (B), plotted against the baseline left ventricular end-systolic volume (LVESV) values, as
determined by echocardiography. There was no correlation between early hemodynamic improvement in PP or dP/dt and baseline left ventricular (LV)
volume. Moreover, long-term volume nonresponders (open circles) were found among high and low early hemodynamic responders, both for PP and
dP/dt, (solid diamonds represent long-term volume responders and stable patients). Three volume nonresponders were among those patients with the
highest acute hemodynamic response.
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for this is a more efficient systolic contraction, which leads
to a reduction in regional wall stress, because areas of
delayed activation, such as the LV free wall in LBBB, are
known to have greater regional wall stress (26). A reduction
in both wall stress and oxygen demand with CRT can lead
to a decrease in sympathetic nervous activation (27), which
may contribute to a reduction in LV size.
Study limitations. The number of patients analyzed was
small, and the changes observed need to be verified in larger
patient cohorts. Because no control group was studied, a
positive effect of the close medical follow-up, rather than
CRT, cannot be ruled out. The cross-over period during the
first three months after implantation may have affected the
results because different pacing modes were used and pa-
tients were not paced during the second month. However,
the differences in the early hemodynamic response between
optimal univentricular (LV in most cases) and BV pacing
were minor (2), and patients were constantly paced for the
last four months before echocardiographic re-evaluation.
Thus, we believe that the data are not invalidated by the
cross-over period. The study was not designed to assess the
impact of CRT on the severity of MR. Thus, no systematic,
prospective evaluation of MR severity was performed. The
modified Simpson’s rule was used for LV volume calcula-
tion, which may not be optimal for the spherical shape and
asymmetrical contraction in the hearts examined. With the
disco-ordinated contraction in LBBB, the smallest cavity
area may not truly represent the end of systole, as late
activated areas may still be contracting. Finally, echocardio-
graphic data have not been correlated to functional vari-
ables.
Conclusions. The data of this study indicate that long-
term CRT leads to a reduction in LV volumes in the
majority of patients with advanced HF and ventricular
conduction disturbances. Patients with higher baseline vol-
umes are less likely to show a decrease in volume. The
mechanisms leading to this “reverse remodeling” effect are
incompletely understood, but may involve a reduction in
regional wall stress, myocardial oxygen demand and func-
tional MR. Further studies in larger patient cohorts are
needed to more clearly define the clinical characteristics of
patients who show reverse remodeling by CRT.
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APPENDIX
The following centers and investigators participated in the
PATH-CHF study (in alphabetical order of centers): Uni-
versity Hospital, Aachen, Germany: C. Stellbrink, B. Diem,
O. A. Breithardt, F. A. Scho¨ndube; University Hospital
Skejky Sygehus, Aarhus, Denmark: P. T. Mortensen, A. K.
Pedersen; University Hospital, Essen, Germany: S. Sack, F.
Heinzel, U. Wolfhard; University Hospital, Magdeburg,
Germany: A. Auricchio (Principal Investigator), H. Klein,
M. Kloss, T. Welte, C. Huth; University Hospital, Mu¨nster,
Germany: M. Block, B. Lamp; Heart and Diabetes Center,
Bad Oeynhausen, Germany: J. Vogt; University Hospital,
Utrecht, The Netherlands: H. Kirkels, P. Bakker.
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